People research BPC-157 and TB-500 together because they get stacked together, usually in the same online “healing” protocols. The honest comparison is less exciting than the marketing: on the two things that decide whether either is worth your attention, the strength of the evidence and the legal status, the two peptides land in almost the same place. The table above is the row-by-row breakdown. Below is what each row actually means.
BPC-157 vs TB-500: the short version
Both are research peptides with animal-level evidence, no published human randomized controlled trial, no approval in any major jurisdiction, and a shared date with the same FDA compounding committee in July 2026. If you are choosing between them hoping one is clearly “more proven” or “more legal” than the other, the data does not support that framing. The meaningful differences are narrow, and the similarities are the headline.
Evidence: both preclinical
Most of what is known about either peptide comes from rodent studies. BPC-157 has a thin layer of human data on top, a few small uncontrolled pilots and, as of 2026, one recruiting Phase 2 trial for acute hamstring strain. TB-500 has no published human trials at all. Neither has a randomized controlled trial, which is the bar for “this works in people”. So the evidence edge, such as it is, tilts very slightly to BPC-157, purely because a human trial exists at all, not because any human efficacy has been shown. For how we decide what counts as evidence, see our how we grade evidence explainer.
Regulation: the same July 2026 vote
Both left the FDA 503A “do not compound” list in April 2026, but that did not make them compoundable. That decision comes from the Pharmacy Compounding Advisory Committee, which votes on both molecules on July 23, 2026. We track the meeting in the July 2026 FDA peptide meeting, explained. Both are also banned for athletes under the WADA S0 category, at all times, with no therapeutic-use exemption available. In the European Union, neither carries a marketing authorization. In other words, every regulatory framework that matters treats the two molecules identically, which is why a buying guide that ranks one over the other on “legality” is selling you a distinction that does not exist.
So which one, if either?
The defensible answer in 2026 is that neither is an established human therapeutic, and the choice between them is a choice between two unproven options. The only concrete, sourced difference is the research pipeline: BPC-157 has a registered human trial in progress and TB-500 does not. Everything else, approval status, compounding status, anti-doping status, is the same. Watch the July 2026 vote for the next real change.
Research information only. Neither BPC-157 nor TB-500 is approved for human use. Talk to a licensed physician before considering any peptide.